Summary
[CanSino Biologics: Novel Coronavirus mRNA Vaccine Receives Drug Clinical Trial Approval from the State Drug Administration]CanSino Biologics announced on the Hong Kong Stock Exchange that the new coronavirus mRNA vaccine developed by the Group has obtained the drug clinical trial approval from the State Drug Administration . The results of preclinical studies show that the vaccine can induce high titers of neutralizing antibodies against a variety of important variants identified by the World Health Organization (including the current circulating strain), which is comparable to the existing new crown vaccine developed based on the prototype strain. Compared with broad-spectrum, it can more effectively protect the body from infection by existing mutants.
CanSinoBiology on HKExannouncement, the novel coronavirus mRNA vaccine developed by the Group has been approved by the State Drug Administration for clinical trials. The results of preclinical studies show that the vaccine can induce high titers of neutralizing antibodies against a variety of important variants identified by the World Health Organization (including current circulating strains), and the existing new crown vaccines developed based on prototype strains Compared with broad-spectrum, it can more effectively protect the body from infection by existing mutants.
(Article source: Financial Associated Press)